GP6
MOLECULAR TARGETglycoprotein VI platelet
GP6 (glycoprotein VI platelet) is targeted by 8 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting GP6
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | ibrutinib | 4.86 | 128 |
| 2 | acalabrutinib | 3.22 | 24 |
| 3 | cinanserin | 2.77 | 15 |
| 4 | zanubrutinib | 2.56 | 12 |
| 5 | evobrutinib | 2.48 | 11 |
| 6 | tirabrutinib | 1.95 | 6 |
| 7 | Losartan | 1.10 | 2 |
| 8 | gamma-Aminobutyric Acid | 0.69 | 1 |
About GP6 as a Drug Target
GP6 (glycoprotein VI platelet) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 8 compounds with documented GP6 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
GP6 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.